id: NEW:sentencing_time_credits_for_moud_to_sud_medication_treatment_rate_oud
name: Sentencing Time Credits for MOUD Initiation â†’ OUD Medication Treatment Rate
from_node:
  node_id: NEW:sentencing_time_credits_for_moud
  node_name: Sentencing Time Credits for MOUD Initiation
to_node:
  node_id: sud_medication_treatment_rate_oud
  node_name: OUD Medication Treatment Rate
direction: positive
category: political
mechanism_pathway:
- 'Step 1: Criminal justice policy provides sentencing time credits (reduced sentence) for individuals
  who initiate extended-release naltrexone'
- 'Step 2: Justice-involved individuals become motivated to seek information about and initiate MOUD to
  reduce their sentence length'
- 'Step 3: Increased MOUD initiation rates among justice-involved population with OUD'
- 'Step 4: Greater exposure to evidence-based treatment during vulnerable reentry period'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: 'Marisa D Booty et al. 2023. "Barriers and facilitators to the use of medication for
    opioid use disorder within the criminal justice system: Perspectives from clinicians.." https://doi.org/10.1016/j.josat.2023.209051'
  supporting_citations:
  - Additional citations require full-text access - qualitative interview study with 25 social service
    clinicians
  - Study references high OUD rates among justice-involved individuals (citation in full text)
  - Study references heightened overdose risk upon release from incarceration (citation in full text)
  doi: 10.1016/j.josat.2023.209051
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: Structural incentives in the form of sentencing time credits facilitate MOUD initiation among
  justice-involved individuals. Clinicians reported clients were motivated to initiate extended-release
  naltrexone specifically because of resulting time off their sentences.
quantitative_effects:
  sample_size: 25
moderators:
- name: type_of_moud
  direction: strengthens
  strength: strong
  description: Time credits specifically available for extended-release naltrexone, not buprenorphine
    or methadone, creating differential access based on medication type
structural_competency:
  equity_implications: This mechanism highlights how criminal justice policy creates structural facilitators
    for treatment access. However, the limitation to extended-release naltrexone creates inequities as
    this may not be the most appropriate medication for all individuals with OUD. Policy could be expanded
    to include all evidence-based MOUD options.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.770898'
  extraction_confidence: medium
  prompt_version: 2.1-canonical-validated
